

FORM PTO-1390(modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 10-95)		ATTORNEY'S DOCKET NUMBER <b>29724</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C., 371		U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR <b>10/538171</b>
INTERNATIONAL APPLICATION NO. <b>PCT/IL03/01057</b>	INTERNATIONAL FILING DATE <b>11 December 2003</b>	PRIORITY DATE CLAIMED <b>12 December 2002</b>
TITLE OF INVENTION <b>GLYCOGEN SYNTHASE KINASE-3 INHIBITORS</b>		
APPLICANT(S) FOR DO/EO/US <b>Hagit ELDAR-FINKELMAN</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371</li> <li><input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li><input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(3)(2)) <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> <li><input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(3)(2)).</li> <li><input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> <li><input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ul> </li> <li><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An <u>unsigned</u> oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li><input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li><input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 13 to 18 below concern document(s) of information included:		
<ol style="list-style-type: none"> <li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li><input type="checkbox"/> Certificate of Mailing by Express Mail</li> <li><input checked="" type="checkbox"/> The sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing</li> <li><input checked="" type="checkbox"/> Other items or information: <b>PCT REQUEST; PRELIMINARY AMENDMENT; FLOPPY DISC WITH SEQUENCE LISTING</b></li> <li><input checked="" type="checkbox"/> <u>85</u> pages of specification (including Abstract page)</li> <li><input checked="" type="checkbox"/> <u>6</u> sheets of drawings</li> <li><input checked="" type="checkbox"/> <u>5</u> pages of sequence listing</li> <li><input checked="" type="checkbox"/> <u>96</u> total pages</li> </ol>		

U.S. APPLICATION NO. (IF KNOWN) See 37 CFR <b>10/538171</b>	INTERNATIONAL APPLICATION NO. PCT/IL03/01057	ATTORNEY'S DOCKET NUMBER <b>29724</b>
--	---	--

**THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:**

FOR:	Column 1 No. FILED	Column 2 No. EXTRA	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
			RATE	Fee	RATE	Fee
Basic National Stage Fee				\$ 150		\$ 300
National Stage Search Fee				\$ 250		\$ 500
National Stage Examination Fee				\$ 100		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			x \$ 125	\$	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$	x \$ 360	\$
Total Claims*	73 - 20=	53	x \$ 25	\$ 1325	x \$50	\$
Independent Claims*	3 - 3=	0	x \$100	\$	x \$200	\$
*	(If the difference in Column 1 is less than "0", enter "0" in Column 2)		<b>TOTAL</b>	<b>\$1825</b>	<b>TOTAL</b>	<b>\$</b>

Please charge my deposit account No. 50-1407 in the amount of \$1,825.00.

A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407.

A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 CFR 1.16.

Any patent application processing fees under 37 CFR 1.17.

The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407.

A duplicate copy of this sheet is enclosed.


Any patent application processing fees under 37 CFR 1.17.

Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Martin Moynihan  
C/O ANTHONY CASTORINA  
SUITE 207  
2001 JEFFERSON DAVIS HIGHWAY  
ARLINGTON, VIRGINIA 22202, USA

  
SIGNATURE  
Martin Moynihan  
NAME  
Martin Moynihan  
REGISTRATION NUMBER  
40,338  
DATE  
7 June 2005